Guía de Práctica Clínica de Tamizaje de Cáncer de Cuello de Útero

Objectives

Uruguay’s cervical cancer guideline supports the National Plan for the Integrated Prevention of Cervical Cancer through an integrated continuum of primary, secondary and tertiary prevention. It seeks to reduce cervical cancer incidence and mortality, detect and treat lesions with malignant potential promptly, and minimise unnecessary procedures, anxiety and other harms.[1][2][3][4]It positions screening within health promotion, prevention, early detection, diagnostic confirmation, treatment, rehabilitation and palliative care, with attention to social determinants of health and women whose sexual and reproductive rights are particularly vulnerable.[1][5]

• Establish an organised, systematic and high-quality population screening programme based principally on conventional cervical cytology, complemented by human papillomavirus vaccination and testing.[6][2]
• Standardise evidence-based clinical practice to reduce unwarranted variation, improve professional decision-making and patient outcomes, and strengthen referral and counter-referral arrangements.[7][2]
• Identify cervical cancer risk factors and support timely detection of pre-invasive and invasive disease.[3][5]
• Apply the routine screening guideline to women aged 21 to 69 who have or have had sexual intercourse, irrespective of sexual practice, and who do not have specified high-risk factors.[5]
• Exclude women with immunosuppression, previous high-grade squamous intraepithelial lesions, adenocarcinoma in situ or invasive cervical cancer from routine recommendations, because they require individualised or separate evidence-based management.[8][4]
• Start screening at age 21, conduct two initial annual cytology tests, and continue three-yearly screening after two normal results.[9][4]
• Stop routine population screening after age 69 for women not at high risk, given the low expected benefit and potential screening-related harms at older ages.[10]
• Use the Bethesda 2001 system to harmonise cervical cytology reporting criteria nationally and internationally.[11]
• Manage abnormal cytology through result- and age-specific pathways, including repeat testing, human papillomavirus testing where available, colposcopy, biopsy, specialist referral and treatment of conditions that may affect cytology results.[10][12]

Implementation

Implementation combines nationally adapted, evidence-based guidance with organised screening, clinical quality standards and coordinated specialist referral. The Ministry of Public Health’s Programme for Comprehensive Women’s Health and Department of Sexual and Reproductive Health coordinate the work, with contributions from the General Directorate of Health, the University of the Republic Faculty of Medicine, the Uruguayan Society of Gynaecology and clinical specialists.[13]The guideline was developed through broad discussion, contribution and validation involving university clinical departments, professional societies, pathology and cytology services, and the Honorary Commission for the Fight Against Cancer.[7]

• Implement human papillomavirus vaccination for the annual cohort of girls reaching 12 years of age alongside organised population screening; vaccination complements rather than replaces screening.[6][2]
• Deliver screening through health-care teams working across promotion, prevention, early detection and diagnostic confirmation.[5]
• Train doctors, midwives and health technicians to counsel patients, obtain informed consent, protect privacy, collect samples and ensure that required supplies are available.[14]
• Follow standardised cytology procedures, including completing the designated form, correctly labelling slides, visualising the transformation zone, taking ectocervical and endocervical samples, promptly fixing specimens and processing them under the Honorary Commission for the Fight Against Cancer laboratory manual.[14]
• Prepare patients by advising avoidance of vaginal intercourse for 48 hours and substances or treatments that could impair interpretation; where possible, collect samples in the first half of the ovarian cycle and avoid menstruation, without delaying assessment of abnormal bleeding.[11]
• Repeat an unsatisfactory cytology test after three months and use defined follow-up routes for atypical or low-grade results, with colposcopy for positive human papillomavirus results, persistent abnormalities or higher-grade lesions.[10][12]
• Refer patients with concerning symptoms, visible lesions, pregnancy-associated lesions, recurrent abnormalities or lesions requiring post-treatment follow-up to appropriate specialist care.[15]
• Provide colposcopy through stable personnel, collaboration with cytology and pathology services, access to ablative, excisional and surgical treatment, and links to gynaecology or gynaecological oncology referral services.[15]
• Maintain auditable clinical records, internal and external quality control, and capacity to track patients through monitoring and treatment; require each accredited colposcopist to manage at least 250 cases annually.[15]
• Develop and update recommendations by defining scope and questions, searching and critically appraising evidence, selecting high-quality guidance, adapting recommendations to the national context, building consensus, conducting external review and securing final approval.[5][16]
• Apply evidence grading based on the Oxford Centre for Evidence-Based Medicine framework and require contributors to declare financial or other interests that may affect independence or objectivity.[16][17][18]

The source links screening effectiveness to high population participation and sustained system quality, and includes evaluation of recommendation application within the guideline-adaptation methodology.[2][5]It does not specify a comprehensive implementation monitoring framework, routine performance indicators, reporting schedule, surveillance system, budget or financing arrangements.[19][5][4]

Monitoring & Evaluation

The guideline’s evaluation approach centres on evidence-based standardisation of cervical cancer screening, clinical quality, appropriate follow-up and professional accountability. It seeks better population morbidity and mortality outcomes, reduced unwarranted variation in care, and avoidance of unnecessary procedures and treatment.[2][3]

• Apply formal guideline-development and adaptation methods, including definition of scope and questions, systematic evidence searching, critical appraisal, selection and adaptation of high-quality recommendations, consensus, external review, reformulation, final approval and evaluation of recommendation application.[5][16]
• Grade evidence and recommendations using the Oxford Centre for Evidence-Based Medicine framework; the guideline identifies grade A, level 1a evidence for starting routine screening at age 21 and stopping routine population screening after age 69, and grade A, level 1b evidence for three-yearly cytology screening.[9][10][17]
• Maintain organised, systematic, high-quality screening with high population participation, as these factors are presented as necessary for screening effectiveness.[6][2]
• Use the Bethesda 2001 system to standardise cytology reporting criteria nationally and internationally.[11]
• Monitor individual clinical follow-up through specified repeat cytology intervals, human papillomavirus testing where available, colposcopy referral and return to routine screening after defined negative results.[10][12]
• Manage unsatisfactory cytology by repeating the Papanicolaou test after three months, and use age- and result-specific pathways for atypical or abnormal cytology.[10][12]
• Maintain auditable clinical records, internal and external quality control, and capacity to follow patients through planned monitoring and treatment.[15]
• Ensure accredited colposcopists manage at least 250 cases annually, alongside stable staffing, collaboration with cytology and pathology services, treatment capacity and referral integration.[15]
• Follow procedural quality requirements for specimen collection and processing, including counselling, informed consent, privacy, correct labelling, prompt fixation and laboratory processing under the named gynaecological cytology laboratory manual.[14]
• Use repeated screening because repeated cytology improves diagnostic sensitivity; reported sensitivity of conventional cytology for high-grade lesions ranges from 30% to 87%.[11]
• Recognise that annual screening offers minimal additional protection compared with three-yearly screening, whereas three-yearly cytology is associated with substantial reductions in cervical cancer incidence and mortality.[9]
• Require contributors and collaborators to submit declarations of interest, with disclosure of financial or other interests, relevant commercial relationships, circumstances affecting objectivity or independence, and subsequent changes.[20][17][18]

No comprehensive implementation monitoring framework is specified in the supplied material. In particular, it does not define a national indicator set, targets, reporting frequency, surveillance architecture, audit cycle, public reporting process, escalation procedure, or a named institution responsible for ongoing programme-performance accountability.[21][19][16][4]

Costing & Financing

The supplied material provides no quantified costing or financing plan for cervical cancer prevention, screening, diagnosis, treatment, referral services or programme monitoring. No budget, financing source, allocation, resource-mobilisation mechanism, funding gap or economic assumption is specified.[21][6][19][11][4][15]

• Anticipate reduced costs associated with inappropriate care through standardised, evidence-based clinical processes and reduced unwarranted variation.[2]
• Limit over-screening and related procedures, assessment and treatment of transient lesions by using three-yearly cytology after two normal annual tests, rather than screening more frequently.[4]
• Require operational inputs such as trained health personnel, counselling and consent processes, collection supplies, cytology forms, laboratory processing, colposcopy capacity, pathology collaboration, treatment access and referral services; however, the material does not quantify their cost or identify how they will be financed.[14][15]
• Present human papillomavirus vaccination and testing as complementary prevention and detection strategies, but do not specify procurement costs, vaccine financing, laboratory expenditure or affordability assumptions.[6][2]

No explicit machine-readable cost items, monetary values, currency denominations, budget periods or funding-gap estimates are available in the supplied extracts.[22][23][24][25][26][27][28][17][18]